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Background: There is an emerging association between ketamine abuse and the development of urological
symptoms including dysuria, frequency and urgency, which have a neurological component. In addition, extreme
cases are associated with severe unresolving bladder pain in conjunction with a thickened, contracted bladder and
an ulcerated/absent urothelium. Here we report on unusual neuropathological features seen by immunohistology
in ketamine cystitis.
Results: In all cases, the lamina propria was replete with fine neurofilament protein (NFP+) nerve fibres and in most
patients (20/21), there was prominent peripheral nerve fascicle hyperplasia that showed particular resemblance to
Morton’s neuroma. The nerve fascicles, which were positive for NFP, S100 and the p75 low-affinity nerve growth
factor receptor (NGFR), were generally associated with a well-developed and in places, prominent, epithelial
membrane antigen+/NGFR+ perineurium. This peripheral nerve fascicle hyperplasia is likely to account for the
extreme pain experienced by ketamine cystitis patients. Urothelial damage was a notable feature of all ketamine
cystitis specimens and where urothelium remained, increased NGFR expression was observed, with expansion from
a basal-restricted normal pattern of expression into the suprabasal urothelium.
Conclusions: The histological findings were distinguishing features of ketamine cystitis and were not present in
other painful bladder conditions. Ketamine cystitis afflicts predominantly young patients, with unknown long-term
consequences, and requires a strategy to control severe bladder pain in order to remove a dependency on the
causative agent. Our study indicates that the development of pain in ketamine cystitis is mediated through a
specific neurogenic mechanism that may also implicate the urothelium.
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CystitisBackground
Ketamine has been used recreationally since the 1970s for
its dissociative and hallucinogenic effects. Since it was first
reported in 2007 [1], there has been an emerging association
between ketamine abuse and the development of severe
uro/neurological symptoms including dysuria, frequency
and urgency in association with a thickened, contracted
bladder (reviewed [2]). Anecdotally, the development of
severe bladder pain may impel continued or even increased
ketamine usage due to the anaesthetic relief it provides [3].
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reproduction in any medium, provided the orto study, and so the full extent and incidence of the problem
within the population is unknown, and poor documentation
of ketamine usage with respect to the development of
functional/structural bladder changes has hindered the
causal and staged mapping of the pathogenic pathway.
Reports of urological symptoms in a minority of patients
prescribed ketamine for chronic pain suggests that some
individuals may be highly susceptible [4,5].
Histological findings reported to-date for ketamine cyst-
itis include an ulcerated urothelium, neovascularisation,
petechial haemorrhages, chronic inflammation/granulation,
lymphocytic infiltration, querciphylloid smooth muscle cells
(containing peripheral vacuoles) and occasional eosinophilia
[1,6-9]. In the absence of an honest case history, ketamine
cystitis may be mistaken histologically for urothelialtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and enlarged nuclei, although the application of histo-
pathological markers such as cytokeratin 20 and p53 can
differentiate [7].
As an emergent condition where there is a suspected
causal agent, it is instructive to compare the pathological fea-
tures of ketamine cystitis to other benign bladder syndromes.
Here we have extended the histopathological study of keta-
mine cystitis to include further specimens and markers, and
compared to a cohort of benign bladder specimens reported
elsewhere [10]. This included interstitial cystitis (IC), a
chronic and often debilitating inflammatory disorder of the
urinary bladder characterised by urinary urgency, frequency
and bladder pain, in the absence of infection. As controls, we
included non-diseased tissue taken during radical prostatec-
tomy (RP), non-inflammatory dysfunctional conditions of
urge urinary incontinence secondary to idiopathic detrusor
overactivity (IDO) and stress urinary incontinence (SUI) as-
sociated with urodynamic stress incontinence [10].
Methods
Tissues
All tissue was collected with NHS Research Ethics
Committee approval and either with informed patient
consent or was used anonymously. Tissue samples
were obtained as cold cut biopsies or cystectomy specimens
from patients with clinically-diagnosed ketamine cystitis.
Some of the ketamine cystitis specimens have been
described previously [7], while others were obtained
from James Cook University Hospital.
A control group of bladder biopsies with no history
of bladder atypia or malignancy (taken during radical
prostatectomies, RP) was included. The series of IC,
IDO and SUI specimens has been described previ-
ously [10]. Briefly, the non-trigone cold-cut biopsies
were obtained from patients diagnosed with IC, urge
urinary incontinence secondary to IDO, or SUI secondary
to urodynamic stress incontinence, according to published
specifications [11,12].
Although there was no statistically significant difference
in the mean (range) age for IC, OAB and GSI, at 51
(25–67), 47 (27–71) and 52 (38–80) years, respectively;
the ketamine cystitis group was much younger at 26
(19–36) and the RP group older at 71 (61–88).Table 1 Antibodies used for immunoperoxidase labelling of h
Antigen Clone/Catalogue number Species Supplier Concentra
EMA E29 Mouse Dako
NGFR 7 F10 Mouse Novocastra
NFP 2 F11 Mouse Dako
S100 Z0311 Rabbit Dako
SMA 1A4 Mouse SigmaImmunohistochemistry
Immunoperoxidase labelling was performed on dewaxed,
formalin-fixed 5 μm tissue sections using the antibodies
and antigen retrieval methods detailed in Table 1.
Blocking steps to neutralise endogeneous peroxidase and
avidin-binding activities were included. Antigen retrieval
for the antibodies raised against epithelial membrane
antigen (EMA), neurofilament protein (NFP) and S100
was performed using “High Retrieval” of 20 min in high
pH solution at 97°C (Dako) and labelling was performed
with an AutostainerLink 48 (Dako).
For the p75 low-affinity nerve growth factor receptor
(NGFR) antibody labelling, heat mediated antigen retrieval
was performed by boiling for 10 min in 10 mM citric
acid buffer (pH 6). The sensitivity of detection of
NGFR immunolabelling was increased using a tyramide-
based amplification system according to the supplier’s
instructions (Dako, UK).
For smooth muscle actin (SMA) labelling, trypsin
digestion (0.1%, w/v, Sigma) was performed for 10 min at
37°C in 0.1% (w/v) CaCl2 (pH 7.8). After overnight
incubation in primary antibody at 4°C, slides were
washed, incubated in biotinylated secondary antibodies and
a streptavidin-biotin horseradish peroxidase complex
(Dako Cytomation) and visualised using a diaminobenzidine
substrate reaction (Sigma-Aldrich).
All sections were counterstained with haematoxylin,
dehydrated and mounted in DPX (CellPath). Positive
and negative specificity controls were included in all
experiments.
Results
Neurogenesis in ketamine cystitis stroma
Urothelial damage was a notable feature of all ketamine
cystitis specimens, with most showing partial loss of
superficial cells and many containing focal full-thickness
urothelial loss (Figure 1A). Haematoxylin and Eosin
staining also revealed prominent nerve fascicles in the
lamina propria of ketamine cystitis patients (Figure 1B).
The stroma of every ketamine cystitis patient tested
was replete with fine NFP+ nerve fibres (Table 2). In
some cases, the nerve fibres were observed in close
proximity to the urothelium, although no fibres could be
detected crossing the basement membrane into theuman bladder biopsies
tion (or dilution factor) Antigen retrieval Tyramide amplification
1:2000 High retrieval No
1:100 Citric acid pH6 Yes
1:3000 High retrieval No
1:6000 High retrieval No
1:4,000 Trypsin digestion No
Figure 1 Representative images from haematoxylin and eosin stained sections of ketamine cystitis tissue. (A) Typical ketamine-induced
changes with increased sub-epithelial capilliarisation and oedema of the lamina propria. In this sample there is early lymphoid aggregate
formation which is not uncommon. The overlying urothelium is reduced to a patchy single layer of epithelial cells showing atypical cytological
changes. (B) Lamina propria with prominent nerve fascicles and conspicuous perineurium; some eosinophils in the background. Scale bar
represents 100 μm.
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labelling was occasionally detected in the stroma of
IDO, SUI and IC samples (Table 2).
NGFR labelling of RP/IDO/SUI bladder stroma was
mostly confined to the blood vessel walls, occasional
interstitial cells and nerve fascicles (arrowed, Figure 3).
NGFR+ labelling was abundant in the stroma of ketamine
cystitis tissues with varying intensity which could not
be directly associated with local urothelial loss. The
NGFR+ lamina propria cells observed in ketamine
cystitis were similar morphologically to myofibroblasts,
but were negative for SMA in serial sections (Figure 3).
NGFR+ labelling also revealed prominent peripheral
nerve fascicle hyperplasia in 20 of 21 ketamine cystitis
biopsies (arrowed, Figure 3), but not in the other bladder
pathologies studied (summarised Table 2).
Further investigation revealed that the NFP+/S100+/NGFR+
nerve fascicles were generally associated with a well-
developed, in places prominent EMA+/NGFR+ peri-
neurium (Figure 4). No Schwannian vaculolar change
or inflammation was noted. The nerve fascicles were
usually identified in the deeper portion of the lamina
propria or within the detrusor muscle, but occasionally
also in the superficial lamina propria (Figure 3).
In places the nerve fascicle-like structures displayed
features reminiscent of the regenerative interstitial changes
in peripheral nerve fascicles seen in neuromas.Table 2 Table summarising graded results of
immunolabelling
Histopathlogical feature IDO SUI IC Ketamine
cystitis
Retention of basal and intermediate
urothelial cells in some areas
5/6 3/4 11/11 16/21
Intense supra-basal expansion of NGFR 1/5 1/3 0/11 10/16
NFP+ in the lamina propria 1/6 1/4 1/11 21/21
Bladder wall neuroma 0/6 0/4 0/11 20/21Urothelial NGFR expansion
NGFR expression was predominantly basally-restricted, but
patchy, in RP, IDO and SUI samples (Figure 5A, B and C).
In 8/11 IC samples, the normal intense basal pattern was
replaced by a weak punctuate labelling throughout the
urothelium (Figure 4D).
In the ketamine cystitis patient group, 16 retained
urothelium including intermediate cells and in 10 of these
samples, expansion of intense basal NGFR expression into
the intermediate compartment was observed (Figure 5E-G).
In the 6 remaining ketamine cystitis samples the NGFR
expression was comparable to RP/IDO/SUI tissues. Where
supra-basal expansion of NGFR+ labelling was observed it
frequently included all but the most superficial layer
(example in Figure 5F&G). This expansion was only
occasionally observed in the other benign bladder
pathology biopsies tested (Table 2).
Discussion
Ketamine cystitis is a growing global problem afflicting
predominantly young patients and exposing them to sig-
nificant risk of bladder damage with unknown long-term
consequences. To-date, there has been little research into
the pathology of ketamine cystitis and as a result, the
mechanism(s) of the bladder pain and damage remain
unknown. This histological study observed expansion of
the basal NGFR+ labelling, stromal nerve hyperplasia and
the occurrence of superficial neuroma-like lesions which
likely contribute to the extreme bladder pain experienced
by ketamine cystitis patients.
The discovery of numerous fine NFP+ nerve fibres
throughout the stroma of ketamine cystitis tissues is
unusual and to our knowledge has not been previously
described. The presence of nerve hyperplasia in ketamine
cystitis tissue in conjunction with urothelial damage
leading to stromal urine exposure may help to account for
the extreme pain experienced by ketamine cystitis patients.
Understanding the mechanism of pain in ketamine cystitis
Figure 2 Representative images of NFP immunohistochemistry in bladder biopsies from ketamine cystitis patients, showing positive
fibres in close proximity, but not infiltrating, the urothelium (left) and large clusters of fibres in the lamina propria (right). Scale bar
represents 100 μm.
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since at present, many ketamine users self-manage their
pain with increased ketamine use. The current lack of
effective clinical pain management for these patients
is a key obstacle to cessation of use [2]. In neuropathic
bladders, there have been reports of nerve hyperplasia
invading the urothelium [13]; however, no NFP+ fibres were
observed within the urothelium in this study. In the small
group of IC patients studied here only a single sample
contained visible NFP+ fibres in the lamina propria. That
this NFP+ IC patient may have been an undisclosed
ketamine user cannot be ruled out; however, the potential
utility of NFP as a biomarker for an IC subgroup with
similarities of pathogenesis to ketamine cystitis warrantsFigure 3 Representative images of NGFR and SMA immunohistochem
and a serial section demonstrating that NGFR+ cells are SMA-. SMA+ la
blood vessels in the bladder wall of ketamine cystitis biopsies. NGFR+ perip
non-diseased bladder taken during radical prostatectomy. Scale bar represefurther investigation. Based on current knowledge, the
discovery of NFP+ fibres in the bladder stroma may be a
useful, if not unequivocal, clinical biomarker of ketamine
cystitis in patients who have non-bacterial cystitis, but do
not provide a history of drug use.
A further novel, and apparently unique, feature of
ketamine cystitis reported here is the appearance of large
peripheral nerve fascicles in the lamina propria, with a
predominant Schwannian and perineural component,
and some resemblance to a Morton’s neuroma. These
lesions appear to arise as a hyperplastic/reactive response
and may be consequential to interstitial regeneration
following ketamine damage. At present, it is unclear how
these changes relate to the degree of pain experienced inistry showing the stromal NGFR+ cells in ketamine cystitis tissue
belling of vascular walls also highlights the appearance of prominent
heral nerve fascicles are arrowed in ketamine cystitis and “control”
nts 100 μm.
Figure 4 Proximal sections showing an example of the NFP+, NGFR+ and S100+ labelling patterns in peripheral nerve fascicle identified
in ketamine cystitis tissue and observed in nearly all ketamine cystitis samples. EMA showed a perineural labelling pattern. The prominent
perineural spindle cell cuff was also NGFR+ and exhibited scanty SMA+ restricted to occasional cells. Note, the adjacent blood vessel, which
showed SMA labelling of the mural smooth muscle cells, but unlike the nerve fascicle was NFP-, NGFR- and S100-. Scale bar represents 100 μm.
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(20/21) urology-referred ketamine cystitis patients in
this study and were not seen in the other bladder
pathologies studied as controls.
The cause of peripheral nerve fascicle hyperplasia in
ketamine cystitis tissues remains unknown; however,
chronic ketamine users (of at least 4 times/week) have
on average twice the serum concentration of brain-
derived neurotrophic factor (BDNF) when compared
with a control group [14]. Further study of ketamine
cystitis will need to address whether the cause of nerve
fascicle hyperplasia is the direct action of ketamine and/
or its metabolites; or alternatively, whether circulating
BDNF could be the causative agent.
The role of NGFR in the urothelium remains an inter-
esting unknown; however, in RP/IDO/SUI tissues it is
most commonly confined to basal urothelial cells. The
expansion of NGFR+ might be indicative of a general de-
differentiation of the tissues; however, no change was
noted for other basal markers (eg CK5) and there wasno disruption of differentiation markers such as
uroplakin 3a (data not shown). Previous studies have
reported increased Ki67 indices in ketamine cystitis
urothelium [7] and interpreted with the supra-basal
NGFR+ expansion reported here, this might suggest
changes in the epithelium towards a regenerative
wound-healing phenotype. This concept is consistent
with the widespread urothelial damage observed in keta-
mine cystitis and retention of uroplakin labelling sug-
gests the urothelium retains a functional barrier in areas
where it remains full-thickness. During cystoscopy of
one patient the urothelium was observed desquamating
from the basement membrane as large sheets, which
was consistent with finding histologically that areas of
intact full-thickness urothelium were directly adjacent to
areas of absent urothelium. Whether the mechanism of
urothelial loss relates to direct toxicity of ketamine or
the action of a metabolite requires further study.
Whilst ketamine was originally described as a NMDA
receptor antagonist, this is a gross oversimplification of
Figure 5 Representative images of NGFR immunohistochemistry showing urothelial localisation in a range of bladder conditions
including “A” non-diseased bladder taken during radical prostatectomy, “B” idiopathic detrusor overactivity and “C” stress urinary
incontinence and “D” interstitial cystitis. Supra-basal expansion of NGFR labelling was only occasionally observed in idiopathic detrusor
overactivity and stress urinary incontinence (see Table 2). In ketamine cystitis biopsies (“E”, “F” & “G”), supra-basal expansion of the intense NGFR
labelling was observed in 10 of the 16 patients who retained intermediate urothelial cells. Scale bar in panel “G” represents 100 μm.
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β-adrenergic, sigma, and muscarinic receptors [15].
Recent interest in using ketamine as a rapid-onset
anti-depressant and pressure to drive derivatives to
market quickly (reviewed [16]), make understanding
the mechanism of ketamine cystitis an urgent clinical
problem to avoid side-effects in future therapeutics.
Conclusions
The results of this study indicate that the severe bladder
pain associated with chronic exposure to ketamine
derives from the combination of a compromised urinary
barrier and widespread nerve hyperplasia in the bladder
wall, including the development of a novel neuroma with
similarities to Morton’s neuroma. This study has alsoshown that the neurogenic changes seen in ketamine cyst-
itis extend to the damaged urothelium, where increased
expression of NGFR makes an unknown contribution to
the pathology. Ketamine cystitis is a debilitating pathology
with long-term consequences for affected young persons
and urgently requires further research to develop effective
treatments.
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